These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25379611

  • 1. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
    Lin X, Liao Y, Xie J, Liu S, Su L, Zou H.
    Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
    [Abstract] [Full Text] [Related]

  • 2. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
    Lin X, Liao Y, Chen X, Long D, Yu T, Shen F.
    Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
    [Abstract] [Full Text] [Related]

  • 3. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
    Lin X, Yu T, Zhang L, Chen S, Chen X, Liao Y, Long D, Shen F.
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
    [Abstract] [Full Text] [Related]

  • 4. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
    Shen F, Long D, Yu T, Chen X, Liao Y, Wu Y, Lin X.
    Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
    [Abstract] [Full Text] [Related]

  • 5. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.
    Chen X, Liao Y, Long D, Yu T, Shen F, Lin X.
    Int J Mol Med; 2017 Jul; 40(1):235-242. PubMed ID: 28534969
    [Abstract] [Full Text] [Related]

  • 6. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
    Long D, Yu T, Chen X, Liao Y, Lin X.
    Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243
    [Abstract] [Full Text] [Related]

  • 7. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
    Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X.
    Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
    [Abstract] [Full Text] [Related]

  • 8. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
    Wu Y, Tang M, Wu Y, Weng X, Yang L, Xu W, Yi W, Gao J, Bode AM, Dong Z, Cao Y.
    Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
    [Abstract] [Full Text] [Related]

  • 9. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
    Feng W, Xiaoyan X, Xuan Y, Xiangke L, Zichang Y, Ran Z, Liuxing W, Qingxia F.
    Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
    [Abstract] [Full Text] [Related]

  • 10. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
    Balasubramani M, Nakao C, Uechi GT, Cardamone J, Kamath K, Leslie KL, Balachandran R, Wilson L, Day BW, Jordan MA.
    Mutat Res; 2011 Jun 17; 722(2):154-64. PubMed ID: 20816848
    [Abstract] [Full Text] [Related]

  • 11. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
    Mistry SJ, Bank A, Atweh GF.
    Mol Cancer Res; 2007 Aug 17; 5(8):773-82. PubMed ID: 17670914
    [Abstract] [Full Text] [Related]

  • 12. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
    Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N.
    Cancer; 2001 Apr 15; 91(8):1494-9. PubMed ID: 11301397
    [Abstract] [Full Text] [Related]

  • 13. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.
    Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, Breuhahn K.
    Hepatology; 2007 Sep 15; 46(3):759-68. PubMed ID: 17663418
    [Abstract] [Full Text] [Related]

  • 14. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
    Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, Swaminathan S, Krishnakumar S.
    Invest Ophthalmol Vis Sci; 2011 Jul 23; 52(8):5441-8. PubMed ID: 21546534
    [Abstract] [Full Text] [Related]

  • 15. In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells.
    Zhao Y, Chen S, Shen F, Long D, Yu T, Wu M, Lin X.
    Oncol Rep; 2019 Jan 23; 41(1):501-511. PubMed ID: 30320402
    [Abstract] [Full Text] [Related]

  • 16. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
    Hata K, Osaki M, Kanasaki H, Nakayama K, Fujiwaki R, Ito H, Miyazaki K.
    Anticancer Res; 2003 Jan 23; 23(2B):1525-31. PubMed ID: 12820419
    [Abstract] [Full Text] [Related]

  • 17. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
    Wang C, Guo LB, Ma JY, Li YM, Liu HM.
    Int J Oncol; 2013 Nov 23; 43(5):1607-17. PubMed ID: 24002547
    [Abstract] [Full Text] [Related]

  • 18. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
    Han ZX, Wang HM, Jiang G, Du XP, Gao XY, Pei DS.
    Cancer Biother Radiopharm; 2013 Jun 23; 28(5):398-405. PubMed ID: 23496232
    [Abstract] [Full Text] [Related]

  • 19. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
    Balachandran R, Welsh MJ, Day BW.
    Oncogene; 2003 Dec 04; 22(55):8924-30. PubMed ID: 14654788
    [Abstract] [Full Text] [Related]

  • 20. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer.
    Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P, Breuhahn K.
    Cancer Res; 2009 Mar 15; 69(6):2234-43. PubMed ID: 19258502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.